Select a modality

HLE BiTE® technology: enhancing features of the BiTE® platform

Engineering BiTE® molecules with a longer half-life

Bispecific T-cell Engager (BiTE®) technology is designed to overcome cancer cells' evasion of the immune system by engaging patients’ own T cells to directly target cancer cells.1,2 BiTE® molecules are engineered to target a selected tumor-associated antigen and CD3 found on T cells.3,4 Canonical BiTE® molecules are designed to be relatively small recombinant proteins that could be cleared through the kidney, with a typical serum half-life of a few hours.3,5

Currently, Amgen is designing half-life extended (HLE) BiTE® molecules containing fragment crystallizable (Fc) domains.6 Adding an Fc portion to a BiTE® molecule is designed to extend the amount of time before it is eliminated from the body.7,8

Download a copy of BiTE The Engager™, an educational resource on BiTE® technology.

 

Search our clinical trials.

Visit our resources section for further information on modalities currently under investigation.

Click here for more information on the BiTE® immuno-oncology platform     

Extending the benefits of BiTE® technology

Canonical BiTE® molecules are designed to be relatively small recombinant proteins that are cleared through the kidney, with a serum half-life of a few hours. Currently, the protein engineers at Amgen are designing BiTE® molecules with enhanced features, including a half-life extended (HLE) BiTE® molecule containing a fragment crystallizable (Fc) domain. Adding an Fc portion to the BiTE® molecule is designed to extend the amount of time before it is eliminated from the body.1-3,5-7

LEARN MORE ABOUT HOW BiTE® TECHNOLOGY ACTIVATES THE CYTOTOXIC POTENTIAL OF T CELLS WITH THE GOAL OF ELIMINATING DETECTABLE CANCER CELLS
Illustration of how BITE molecules with a longer half-life can engage endogenous T cells to cancer cells
ENLARGE IMAGE TO LEARN MORE ABOUT BiTE® TECHNOLOGY
HLE BiTE® video
SEE BiTE® TECHNOLOGY IN ACTION
HLE BiTE® molecules are under investigation to target9,10:
Clinical trials are underway in several cancers, including9:

BCMA: B-cell maturation antigen; BiTE: Bispecific T-cell Engager; CD: cluster of differentiation; CLDN18.2: Claudin-18 isoform 2; DLL3: delta-like protein 3; FLT3: FMS-like tyrosine kinase 3; GEJ: gastroesophageal junction; HLE: half-life extended; MUC17: mucin17; PSMA: prostate-specific membrane antigen.

References

1. Baeuerle PA, Kufer P, Bargou R. Curr Opin Mol Ther. 2009;11(1):22-30. 2. Frankel SR, Baeuerle PA. Curr Opin Chem Biol. 2013;17(3):385-392. 3. Yuraszeck T, Kasichayanula S, Benjamin JE. Clin Pharmacol Ther. 2017;101(5):634-645. 4. Nagorsen D, Baeuerle PA. Exp Cell Res. 2011;317(9):1255-1260. 5. Thakur A, Huang M, Lum LG. Blood Rev. 2018;32(4):339-347. 6. Raum T, Münz M, Brozy J, inventors. US Patent 2017/0218077A1. 8/3/2017. 7. Weidle UH, Tiefenthaler G, Weiss EH, et al. Cancer Genomics Proteomics. 2013;10(1):1-18. 8. Arvedson TL, Balazs M, Bogner P, et al. Cancer Res. 2017;77(suppl 13):Abstract 55. 9. Amgen. Amgen pipeline. https://www.amgenpipeline.com/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf. Accessed 4/8/2020. 10. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04260191. Accessed 4/21/2020.